Compare fund portfolios
See how two funds' portfolios overlap. Enter two tickers:
FBTIX vs FMED
Shared holdings
33
FBTIX covered by FMED
34.88%
FMED covered by FBTIX
34.88%
Coverage = share of one portfolio's weight reproduced by the other (overlapping positions, min weight). Top 50 positions per side shown; = held by both — hover a shared position to highlight it in both columns.
FBTIX (Jan. 31, 2026)
| Security | Weight | |
|---|---|---|
| ABBVIE INC | 16.04% | |
| GILEAD SCIENCES INC | 6.35% | |
| ALNYLAM PHARMACEUTICALS INC | 4.85% | |
| Ascendis Pharma A/S | 4.34% | |
| COGENT BIOSCIENCES INC | 3.70% | |
| ARGENX SE SPONSORED ADR | 3.52% | |
| Fidelity Securities Lending Cash Central Fund | 3.47% | |
| INSMED INC | 3.35% | |
| VIRIDIAN THERAPEUTICS INC | 3.05% | |
| BIOGEN INC | 2.74% | |
| AMGEN INC | 2.67% | |
| VAXCYTE INC | 2.21% | |
| STRUCTURE THERAPEUTICS INC ADR | 2.20% | |
| NUVALENT INC-A | 2.20% | |
| DIANTHUS THERAPEUTICS INC | 2.02% | |
| AMYLYX PHARMACEUTICALS INC | 1.80% | |
| MODERNA INC | 1.54% | |
| APOGEE THERAPEUTICS INC | 1.54% | |
| XENON PHARMACEUTICALS INC | 1.51% | |
| CRINETICS PHARMACEUTICALS INC | 1.41% | |
| PRAXIS PRECISION MEDICINES INC | 1.40% | |
| SCHOLAR ROCK HOLDING CORP | 1.34% | |
| ORUKA THERAPEUTICS INC | 1.26% | |
| SPYRE THERAPEUTICS INC | 1.24% | |
| UCB SA | 1.19% | |
| UNIQURE N.V. | 1.17% | |
| UPSTREAM BIO INC | 1.11% | |
| ROIVANT SCIENCES LTD | 1.09% | |
| NATERA INC | 1.07% | |
| OLEMA PHARMACEUTICALS INC | 1.04% | |
| VIKING THERAPEUTICS INC | 0.97% | |
| NEWAMSTERDAM PHARMA COMPANY NV | 0.94% | |
| CYTOKINETICS INC | 0.93% | |
| KYMERA THERAPEUTICS INC | 0.87% | |
| JADE BIOSCIENCES INC | 0.72% | |
| CG ONCOLOGY INC | 0.67% | |
| RHYTHM PHARMACEUTICALS INC | 0.67% | |
| ENLIVEN THERAPEUTICS INC | 0.65% | |
| ZENAS BIOPHARMA INC | 0.60% | |
| DISC MEDICINE INC | 0.57% | |
| ARCELLX INC | 0.51% | |
| STOKE THERAPEUTICS INC | 0.50% | |
| SONOMA BIOTHERAPEUTICS INC SER B PFD PP | 0.49% | |
| TRAVERE THERAPEUTICS INC | 0.48% | |
| MINERALYS THERAPEUTICS INC | 0.43% | |
| CYTOMX THERAPEUTICS INC | 0.40% | |
| ANAPTYSBIO INC | 0.36% | |
| SOLENO THERAPEUTICS INC | 0.36% | |
| CELLDEX THERAPEUTICS INC | 0.35% | |
| REZOLUTE INC | 0.34% |
FMED (Feb. 28, 2026)
| Security | Weight | |
|---|---|---|
| Fidelity Securities Lending Cash Central Fund | 11.15% | |
| DANAHER CORP | 3.77% | |
| UCB SA | 3.61% | |
| BOSTON SCIENTIFIC CORP | 3.58% | |
| ARGENX SE SPONSORED ADR | 3.41% | |
| COGENT BIOSCIENCES INC | 3.40% | |
| ALNYLAM PHARMACEUTICALS INC | 2.94% | |
| INTUITIVE SURGICAL INC | 2.79% | |
| VEEVA SYSTEMS-A | 2.65% | |
| INSULET CORP | 2.29% | |
| MODERNA INC | 2.28% | |
| WAYSTAR HOLDING CORP | 2.24% | |
| EDWARDS LIFESCIENCES CORP | 2.20% | |
| LIFESTANCE HEALTH GROUP INC | 2.18% | |
| VAXCYTE INC | 2.03% | |
| INSMED INC | 1.74% | |
| Sartorius Stedim Biotech S.A. | 1.74% | |
| STRYKER CORP | 1.65% | |
| LILLY ELI and CO | 1.58% | |
| PRIVIA HEALTH GROUP INC | 1.56% | |
| THERMO FISHER SCIENTIFIC INC | 1.55% | |
| LEGEND BIOTECH CORP SPON ADR | 1.53% | |
| 10X GENOMICS INC | 1.51% | |
| PENUMBRA INC | 1.51% | |
| KYMERA THERAPEUTICS INC | 1.33% | |
| STOKE THERAPEUTICS INC | 1.33% | |
| Ascendis Pharma A/S | 1.32% | |
| UNITEDHEALTH GRP | 1.27% | |
| NATERA INC | 1.27% | |
| LONZA GROUP -REG | 1.26% | |
| CYTOKINETICS INC | 1.20% | |
| CARIS LIFE SCIENCES INC | 1.17% | |
| CRINETICS PHARMACEUTICALS INC | 1.14% | |
| DEXCOM INC | 1.12% | |
| DISC MEDICINE INC | 1.08% | |
| VERACYTE INC | 1.07% | |
| RESMED INC | 1.05% | |
| XENON PHARMACEUTICALS INC | 0.99% | |
| CENTESSA PHARMACEUTICALS LTD ADR | 0.89% | |
| NUVALENT INC-A | 0.89% | |
| CYTOMX THERAPEUTICS INC | 0.88% | |
| ALIGNMENT HEALTHCARE INC | 0.84% | |
| ALIGN TECHNOLOGY INC | 0.83% | |
| GUARDANT HEALTH INC | 0.82% | |
| WAVE LIFE SCIENCES LTD | 0.81% | |
| KINIKSA PHARMACEUTICALS INTERNATIONAL PLC | 0.78% | |
| ROIVANT SCIENCES LTD | 0.76% | |
| REPLIGEN CORP | 0.74% | |
| ENLIVEN THERAPEUTICS INC | 0.74% | |
| BIO-TECHNE CORP | 0.72% |
Machine-readable: JSON · Markdown. Programmatic access via the agent surface.